Development of a low-dose anti-resorptive drug regimen reveals synergistic suppression of bone formation when coupled with disuse

Journal of Applied Physiology

Volumn 104, Issue 3, 2008, Pages 729-738

  Lloyd, Shane A J ^a,b   Travis, Neil D ^b   Lu, Teng ^b   Bateman, Ted A ^b,c  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b AMRL   (United States)

^c CLEMSON UNIVERSITY   (United States)

Author keywords

Bone loss; Microcomputed tomography; Osteoporosis; Osteoprotegerin; Spaceflight; Zoledronic acid

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; DENOSUMAB; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; RECLAST; UNCLASSIFIED DRUG; ZOLEDRONIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BIOMECHANICS; BONE REMODELING; CONTROLLED STUDY; COSMONAUT; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG POTENTIATION; FEMALE; FEMUR; HINDLIMB; MICRO-COMPUTED TOMOGRAPHY; MINERALIZATION; MORPHOMETRICS; MOUSE; NONHUMAN; OSSIFICATION; OSTEOBLAST; OSTEOLYSIS; OSTEOPOROSIS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROPHYLAXIS; QUANTITATIVE ANALYSIS; SPACE FLIGHT; TRABECULAR BONE; TREATMENT RESPONSE;

ANIMALS; BIOMECHANICS; BONE DENSITY CONSERVATION AGENTS; BONE RESORPTION; CALCIFICATION, PHYSIOLOGIC; DIPHOSPHONATES; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FEMUR; HINDLIMB SUSPENSION; IMIDAZOLES; MICE; MICE, INBRED C57BL; OSTEOBLASTS; OSTEOGENESIS; OSTEOPOROSIS; OSTEOPROTEGERIN; SPACE FLIGHT; TOMOGRAPHY, X-RAY COMPUTED; WEIGHTLESSNESS COUNTERMEASURES;

EID: 41549148147     PISSN: 87507587     EISSN: 15221601     Source Type: Journal    
DOI: 10.1152/japplphysiol.00632.2007     Document Type: Article

References (39)

1. Bateman TA, Dunstan CR, Ferguson VL, Lacey DL, Ayers RA, Simske SJ. Osteoprotegerin mitigates tail suspension-induced osteopenia. Bone 26: 443-449, 2000.
2. Bekker PJ, Holloway DL, Rasmussen AS, Murphy R, Martin SW, Leese PT, Holmes GB, Dunstan CR, DePaoli AM. A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women. J Bone Miner Res 19: 1059-1066, 2004.
3. Black DM, Delmas PD, Eastell R, Reid IR, Boonen S, Cauley JA, Cosman F, Lakatos P, Leung PC, Man Z, Mautalen C, Mesenbrink P, Hu H, Caminis J, Tong K, Rosario-Jansen T, Krasnow J, Hue TF, Sellmeyer D, Eriksen EF, Cummings SR. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 356: 1809-1822, 2007.
4. Black DM, Greenspan SL, Ensrud KE, Palermo L, McGowan JA, Lang TF, Garnero P, Bouxsein ML, Bilezikian JP, Rosen CJ. The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. N Engl J Med 349: 1207-1215, 2003.
5. Body JJ, Lortholary A, Romieu G, Vigneron AM, Ford J. A dose-finding study of zoledronate in hypercalcemic cancer patients. J Bone Miner Res 14: 1557-1561, 1999.
6. Boyle WJ, Simonet WS, Lacey DL. Osteoclast differentiation and activation. Nature 423: 337-342, 2003.
7. Broz JJ, Simske SJ, Greenberg AR, Luttges MW. Effects of rehydration state on the flexural properties of whole mouse long bones. J Biomech Eng 115: 447-449, 1993.
8. Cryer B, Binkley N, Simonelli C, Lewiecki EM, Lanza F, Chen E, Petruschke RA, Mullen C, de Papp AE. A randomized, placebo-controlled, 6-month study of once-weekly alendronate oral solution for postmenopausal osteoporosis. Am J Geriatr Pharmacother 3: 127-136, 2005.
9. Dempster DW, Cosman F, Kurland ES, Zhou H, Nieves J, Woelfert L, Shane E, Plavetic K, Muller R, Bilezikian J, Lindsay R. Effects of daily treatment with parathyroid hormone on bone microarchitecture and turnover in patients with osteoporosis: a paired biopsy study. J Bone Miner Res 16: 1846-1853, 2001.
10. Ding M, Day JS, Burr DB, Mashiba T, Hirano T, Weinans H, Sumner DR, Hvid I. Canine cancellous bone microarchitecture after one year of high-dose bisphosphonates. Calcif Tissue Int 72: 737-744, 2003.
11. Finkelstein JS, Hayes A, Hunzelman JL, Wyland JJ, Lee H, Neer RM. The effects of parathyroid hormone, alendronate, or both in men with osteoporosis. N Engl J Med 349: 1216-1226, 2003.
12. Finkelstein JS, Leder BZ, Burnett SM, Wyland JJ, Lee H, de la Paz AV, Gibson K, Neer RM. Effects of teriparatide, alendronate, or both on bone turnover in osteoporotic men. J Clin Endocrinol Metab 91: 2882-2887, 2006.
13. Fleisch HA. Bisphosphonates: preclinical aspects and use in osteoporosis. Ann Med 29: 55-62, 1997.
14. Gallagher JC. Role of estrogens in the management of postmenopausal bone loss. Rheum Dis Clin North Am 27: 143-162, 2001.
15. Globus RK, Bikle DD, Morey-Holton E. The temporal response of bone to unloading. Endocrinology 118: 733-742, 1986.
16. Greenspan SL, Harris ST, Bone H, Miller PD, Orwoll ES, Watts NB, Rosen CJ. Bisphosphonates: safety and efficacy in the treatment and prevention of osteoporosis. Am Fam Physician 61: 2731-2736, 2000.
17. Howard GA, Bottemiller BL, Turner RT, Rader JI, Baylink DJ. Parathyroid hormone stimulates bone formation and resorption in organ culture: evidence for a coupling mechanism. Proc Natl Acad Sci USA 78: 3204-3208, 1981.
18. Judex S, Boyd S, Qin YX, Miller L, Muller R, Rubin C. Combining high-resolution micro-computed tomography with material composition to define the quality of bone tissue. Curr Osteoporos Rep 1: 11-19, 2003.
19. Lane HW, Smith SM. Physiological adaptations to space flight. Life Support Biosph Sci 6: 13-18, 1999.
20. Lang T, LeBlanc A, Evans H, Lu Y, Genant H, Yu A. Cortical and trabecular bone mineral loss from the spine and hip in long-duration spaceflight. J Bone Miner Res 19: 1006-1012, 2004.
21. Lang TF, Leblanc AD, Evans HJ, Lu Y. Adaptation of the proximal femur to skeletal reloading after long-duration spaceflight. J Bone Miner Res 21: 1224-1230, 2006.
22. Lawler A. Space exploration. Scientists add up gains, losses in Bush's new vision for NASA. Science 303: 444-445, 2004.
23. LeBlanc AD, Driscol TB, Shackelford LC, Evans HJ, Rianon NJ, Smith SM, Feeback DL, Lai D. Alendronate as an effective counter-measure to disuse induced bone loss. J Musculoskelet Neuronal Interact 2: 335-343, 2002.
24. Markin AA, Zhuravleva OA, Morukov BV, Vostrikova LV, Zabolotskaia IV, Poluektova VP. [Characteristics of cosmonauts' metabolism after extended missions on the international space station]. Aviakosm Ekolog Med 39: 36-41, 2005.
25. Martin TJ. Hormones in the coupling of bone resorption and formation. Osteoporos Int 3, Suppl 1: 121-125, 1993.
26. McClung MR, Lewiecki EM, Cohen SB, Bolognese MA, Woodson GC, Moffett AH, Peacock M, Miller PD, Lederman SN, Chesnut CH, Lain D, Kivitz AJ, Holloway DL, Zhang C, Peterson MC, Bekker PJ. Denosumab in postmenopausal women with low bone mineral density. N Engl J Med 354: 821-831, 2006.
27. Midura RJ, Su X, Androjna C. A simulated weightlessness state diminishes cortical bone healing responses. J Musculoskelet Neuronal Interact 6: 327-328, 2006.
28. Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster JY, Hodsman AB, Eriksen EF, Ish-Shalom S, Genant HK, Wang O, Mitlak BH. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 344: 1434-1441, 2001.
29. Parfitt AM, Drezner MK, Glorieux FH, Kanis JA, Malluche H, Meunier PJ, Ott SM, Recker RR. Bone histomorphometry: standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee. J Bone Miner Res 2: 595-610, 1987.
30. Rodan GA, Fleisch HA. Bisphosphonates: mechanisms of action. J Clin Invest 97: 2692-2696, 1996.
31. Simske SJ, Greenberg AR, Luttges MW. Effects of suspension-induced osteopenia on the mechanical behaviour of mouse long bones. J Mater Sci Mater Med 2: 43-50, 1991.
32. Simske SJ, Guerra KM, Greenberg AR, Luttges MW. The physical and mechanical effects of suspension-induced osteopenia on mouse long bones. J Biomech 25: 489-499, 1992.
33. Smith SM, Wastney ME, Morukov BV, Larina IM, Nyquist LE, Abrams SA, Taran EN, Shih CY, Nillen JL, Davis-Street JE, Rice BL, Lane HW. Calcium metabolism before, during, and after a 3-mo space-flight: kinetic and biochemical changes. Am J Physiol Regul Integr Comp Physiol 277: R1-R10, 1999.
34. Smith SM, Wastney ME, O'Brien KO, Morukov BV, Larina IM, Abrams SA, Davis-Street JE, Oganov V, Shackelford LC. Bone markers, calcium metabolism, and calcium kinetics during extended-duration space flight on the mir space station. J Bone Miner Res 20: 208-218, 2005.
35. Tesch PA, Berg HE, Bring D, Evans HJ, LeBlanc AD. Effects of 17-day spaceflight on knee extensor muscle function and size. Eur J Appl Physiol 93: 463-468, 2005.
36. Tilton FE, Degioanni JJ, Schneider VS. Long-term follow-up of Skylab bone demineralization. Aviat Space Environ Med 51: 1209-1213, 1980.
37. Tommasini SM, Nasser P, Schaffler MB, Jepsen KJ. Relationship between bone morphology and bone quality in male tibias: implications for stress fracture risk. J Bone Miner Res 20: 1372-1380, 2005.
38. Vico L, Collet P, Guignandon A, Lafage-Proust MH, Thomas T, Rehaillia M, Alexandre C. Effects of long-term microgravity exposure on cancellous and cortical weight-bearing bones of cosmonauts. Lancet 355: 1607-1611, 2000.
39. Zayzafoon M, Meyers VE, McDonald JM. Microgravity: the immune response and bone. Immunol Rev 208: 267-280, 2005.